Literature DB >> 26531720

Circulating miR-148/152 family as potential biomarkers in hepatocellular carcinoma.

Feng Wang1, Houqun Ying2, Bangshun He1, Yuqin Pan1, Huiling Sun1, Shukui Wang3.   

Abstract

Aberrant expressions of the miR-148/152 family (miR-148a, miR-148b, and miR-152) have been documented in many tumor tissues, including hepatocellular carcinoma (HCC). However, the expression pattern and clinical significance of circulating miR-148/152 family in HCC remain elusive. In this study, we conducted quantitative real-time polymerase chain reaction (qRT-PCR) to examine the levels of serum miR-148a, miR-148b, and miR-152 in 76 HCC cases, as well as 62 controls with benign liver diseases and 55 healthy volunteers. Our results showed that serum levels of three microRNAs (miRNAs) were significantly decreased in HCC cases than those in benign and healthy controls (all P < 0.05). Moreover, they showed strong correlations with each other in HCC group (r = 0.6716, 0.5381, and 0.7712; all P < 0.001). Receiver operating characteristic (ROC) analysis revealed that the combination of circulating miR-148/152 family had an increased area under the curve (AUC) = 0.940 (95 % confidence interval (CI), 0.886-0.973) with the sensitivity of 96.1 % and the specificity of 91.9 %, which were significantly higher than those of serum alpha-fetoprotein (AFP) and three miRNAs alone in differentiating HCC from benign liver diseases. In addition, serum miR-148a and miR-148b were significantly associated with tumor size (P = 0.011 and 0.037) and tumor-node-metastasis (TNM) stage (P < 0.001 and P = 0.034), yet serum miR-152 was only correlated with TNM stage (P = 0.009). Also, dynamic monitoring three miRNAs can help us predict recurrence or metastasis in HCC cases after surgical resection. Besides, Kaplan-Meier analyses demonstrated that the decreased serum miR-148a (P < 0.001) and miR-152 (P = 0.012) was closely correlated with shorten overall survival of HCC patients. Additionally, Cox regression model further indicated that serum miR-148a was strongly associated with the prognosis of HCC patients. Our study suggests that downregulated circulating miR-148/152 family can provide positive diagnostic value for HCC. Moreover, serum miR-148a might be as independent prognostic factor for HCC patients.

Entities:  

Keywords:  Biomarker; Hepatocellular carcinoma; miR-148a; miR-148b; miR-152

Mesh:

Substances:

Year:  2015        PMID: 26531720     DOI: 10.1007/s13277-015-4340-z

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  34 in total

1.  MicroRNA-148a suppresses the epithelial-mesenchymal transition and metastasis of hepatoma cells by targeting Met/Snail signaling.

Authors:  J-P Zhang; C Zeng; L Xu; J Gong; J-H Fang; S-M Zhuang
Journal:  Oncogene       Date:  2013-09-09       Impact factor: 9.867

2.  miR-152 suppresses gastric cancer cell proliferation and motility by targeting CD151.

Authors:  Ronglin Zhai; Xuefeng Kan; Bo Wang; Hansong Du; Yueping Long; Heshui Wu; Kaixiong Tao; Guobin Wang; Lihong Bao; Fen Li; Wanli Zhang
Journal:  Tumour Biol       Date:  2014-08-15

3.  Emerging trends in hepatocellular carcinoma incidence and mortality.

Authors:  Basile Njei; Yaron Rotman; Ivo Ditah; Joseph K Lim
Journal:  Hepatology       Date:  2014-11-24       Impact factor: 17.425

4.  Down-regulated microRNA-152 induces aberrant DNA methylation in hepatitis B virus-related hepatocellular carcinoma by targeting DNA methyltransferase 1.

Authors:  Jinfeng Huang; Yue Wang; Yingjun Guo; Shuhan Sun
Journal:  Hepatology       Date:  2010-07       Impact factor: 17.425

Review 5.  MicroRNAs as potential biomarkers in cancer: opportunities and challenges.

Authors:  Huiyin Lan; Haiqi Lu; Xian Wang; Hongchuan Jin
Journal:  Biomed Res Int       Date:  2015-03-22       Impact factor: 3.411

6.  miRNA-148b suppresses hepatic cancer stem cell by targeting neuropilin-1.

Authors:  Qinying Liu; Yangmei Xu; Shenghong Wei; Wei Gao; Li Chen; Tong Zhou; Zhen Wang; Mingang Ying; Qiuhong Zheng
Journal:  Biosci Rep       Date:  2015-05-22       Impact factor: 3.840

7.  MiR-148b suppresses cell proliferation and invasion in hepatocellular carcinoma by targeting WNT1/β-catenin pathway.

Authors:  Jun-gang Zhang; Ying Shi; De-fei Hong; Mengqi Song; Dongsheng Huang; Chun-you Wang; Gang Zhao
Journal:  Sci Rep       Date:  2015-01-28       Impact factor: 4.379

Review 8.  Circulating miRNAs in cancer: from detection to therapy.

Authors:  Wen-Tao Wang; Yue-Qin Chen
Journal:  J Hematol Oncol       Date:  2014-12-05       Impact factor: 17.388

Review 9.  The microRNA-148/152 family: multi-faceted players.

Authors:  Yue Chen; Yong-Xi Song; Zhen-Ning Wang
Journal:  Mol Cancer       Date:  2013-05-19       Impact factor: 27.401

Review 10.  miRNA biogenesis: biological impact in the development of cancer.

Authors:  Sandra L Romero-Cordoba; Ivan Salido-Guadarrama; Mauricio Rodriguez-Dorantes; Alfredo Hidalgo-Miranda
Journal:  Cancer Biol Ther       Date:  2014       Impact factor: 4.742

View more
  12 in total

1.  circMRPS35 promotes malignant progression and cisplatin resistance in hepatocellular carcinoma.

Authors:  Peng Li; Runjie Song; Fan Yin; Mei Liu; Huijiao Liu; Shuoqian Ma; Xiaomeng Jia; Xiaohui Lu; Yuting Zhong; Lei Yu; Xiru Li; Xiangdong Li
Journal:  Mol Ther       Date:  2021-08-25       Impact factor: 11.454

2.  Prognostic value of microRNAs in hepatocellular carcinoma: a meta-analysis.

Authors:  Yue Zhang; Chao Wei; Cong-Cong Guo; Rong-Xiu Bi; Jin Xie; Dong-Hui Guan; Chuan-Hua Yang; Yue-Hua Jiang
Journal:  Oncotarget       Date:  2017-09-14

3.  The significance of microRNA-148/152 family as a prognostic factor in multiple human malignancies: a meta-analysis.

Authors:  Chenkui Miao; Jianzhong Zhang; Kai Zhao; Chao Liang; Aiming Xu; Jundong Zhu; Yuhao Wang; Yibo Hua; Ye Tian; Shouyong Liu; Chao Zhang; Chao Qin; Zengjun Wang
Journal:  Oncotarget       Date:  2017-06-27

4.  Serum exosomal microRNAs combined with alpha-fetoprotein as diagnostic markers of hepatocellular carcinoma.

Authors:  Yurong Wang; Chunyan Zhang; Pengjun Zhang; Guanghong Guo; Tao Jiang; Xiumei Zhao; Jingjing Jiang; Xueliang Huang; Hongli Tong; Yaping Tian
Journal:  Cancer Med       Date:  2018-03-23       Impact factor: 4.452

Review 5.  Biomarkers in Hepatocellular Carcinoma: Diagnosis, Prognosis and Treatment Response Assessment.

Authors:  Federico Piñero; Melisa Dirchwolf; Mário G Pessôa
Journal:  Cells       Date:  2020-06-01       Impact factor: 6.600

Review 6.  Assessment of miR-98-5p, miR-152-3p, miR-326 and miR-4289 Expression as Biomarker for Prostate Cancer Diagnosis.

Authors:  Leire Moya; Jonelle Meijer; Sarah Schubert; Farhana Matin; Jyotsna Batra
Journal:  Int J Mol Sci       Date:  2019-03-06       Impact factor: 5.923

Review 7.  The Diagnostic Value of MicroRNAs as a Biomarker for Hepatocellular Carcinoma: A Meta-Analysis.

Authors:  Yao Jiang; Jimin He; Yiqin Li; Yongcan Guo; Hualin Tao
Journal:  Biomed Res Int       Date:  2019-11-29       Impact factor: 3.411

8.  Function of miR-152 as a Tumor Suppressor in Human Breast Cancer by Targeting PIK3CA.

Authors:  Shuke Ge; Dan Wang; Qinglong Kong; Wei Gao; Jiayi Sun
Journal:  Oncol Res       Date:  2017-02-28       Impact factor: 5.574

9.  Evaluating the prognostic value of miR-148/152 family in cancers: based on a systemic review of observational studies.

Authors:  Fujiao Duan; Weigang Liu; Xiaoli Fu; Yajing Feng; Liping Dai; Shuli Cui; Zhenxing Yang
Journal:  Oncotarget       Date:  2017-09-11

10.  Inverse relationship between the level of miRNA 148a-3p and both TGF-β1 and FIB-4 in hepatocellular carcinoma.

Authors:  Ashraf A Dawood; Amany A Saleh; Osama Elbahr; Suzy Fawzy Gohar; Mona S Habieb
Journal:  Biochem Biophys Rep       Date:  2021-07-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.